Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equ...
January 12 2017 - 9:30PM
Business Wire
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose
monitoring (CGM) for people with diabetes, is pleased to announce
the determination of a benefit category and coverage for CGM by
CMS. In order to be included in this category, the system must be
defined as “therapeutic” CGM, meaning you can make treatment
decisions using the device. Today, the Dexcom G5 Mobile is the only
CGM system that falls within this classification. A link to the
full CMS Ruling No. CMS-1682-R can be found at
www.cms.gov/Regulations-and-Guidance/Guidance/Rulings/Downloads/CMS1682R.pdf.
“This landmark CMS Ruling will make available the most important
technology in diabetes management to the Medicare population,” said
Kevin Sayer, Dexcom President and Chief Executive Officer. “We are
pleased with this important step forward and we look forward to
working with Medicare on implementing coverage in the coming months
to ensure beneficiaries have access to this life-saving
device.”
About Diabetes and Continuous Glucose Monitoring
With diabetes, the body cannot produce or use the hormone
insulin effectively, causing a buildup of glucose, or sugar, in the
blood. People with diabetes who take insulin must monitor their
blood glucose levels frequently. Uncontrolled glucose can cause
health complications and even death.i,ii
Continuous glucose monitoring (CGM) is considered the most
significant breakthrough in diabetes management in the past 40
years.iii CGM is important because, in addition to providing the
glucose level, it provides the direction and rate of glucose change
with the push of a button and alerts users when glucose is too low
or too high with built-in and customizable alarms. A recent study
showed that after one year, patients with type 1 diabetes who used
CGM alone had significant A1C reductions regardless of the type of
insulin delivery method used, including insulin pumps.iv
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated
to helping people better manage their diabetes by developing and
marketing continuous glucose monitoring (CGM) products and tools
for adult and pediatric patients. With exceptional performance,
patient comfort and lifestyle flexibility at the heart of its
technology, users have consistently ranked DexCom highest
in customer satisfaction and loyalty. For more information on the
DexCom CGM, visit www.dexcom.com.
References
i Hyperglycemia (High blood glucose). American Diabetes
Association Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.
Updated August 5, 2013. Accessed December 3, 2013.
ii Hypoglycemia (Low blood glucose). American Diabetes
Association Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.
Updated July 16, 2013. Accessed December 3, 2013.
iii Clarke SF and Foster JR. A history of blood glucose meters
and their role in self-monitoring of diabetes mellitus. Br J Biomed
Sci. 2012;(3)2:83-93.
iv J. Soupal, J. Skrha Prazny, M. Flekac, L. Petruzelkova, J.
Skrha, et al. Comparison of different treatment modalities for Type
1 diabetes including Sensor-Augmented Insulin Regimens (SAIR), in
52 weeks of follow ups: A COMISAIR Study. Diabetes Technology and
Therapeutics. Vol 18, No. 9, Sept. 2016.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170112006146/en/
DexCom, Inc.Investor Contact:Steve Pacelli, 858-200-0200orPress
Contact:Melissa Katz, 215-514-0957
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024